Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Was it this one ...2020?
https://www.sharesoc.org/seminar/sharesoc-webinar-with-synairgen-sng-18-november-2020/
Thanks Tommy.
So 20k studied which is a pretty large study.
Interesting that the Eua etc was for those on oxygen, but it was still being given to people not on oxygen. Its that a breach of the terms of use?
It looks like the criteria needs to be clarified somewhat. Perhaps if given once a patient was on high flow oxygen that would leave a nice little niche for SNG001.
Also there seems to be research there may be benefit for interferons followed by steroids, but not if steroids are given first.
It's nice to be reminded of the subgroup analysis...
70% of those on low-flow oxygen, sats less than 92% and resps over 21 bmp showed improvement and less likely to progress to severe illness or death.
This is why we need that trial. We do know it works... Just need to prove it beyond doubt.
It looks like there are a couple of sub-lineages coming out that they think can reinfect people who have already had an earlier omicron varient.
Order rejected... Never had that before.
Same for buy or sell
It looks like that's one of the reasons it is so infectious. Huge amounts of virus in the right place to get expelled passed onto someone else.
Less replication in lung tissue though, so more time for infB to have an effect, maybe?
Don't know where the 'ha' came from?!!
https://amp-theguardian-com.cdn.ampproject.org/v/s/amp.theguardian.com/world/2021/dec/15/omicron-found-to-grow-70-times-faster-than-delta-in-bronchial-tissue?amp_js_v=a6&_gsa=1&usqp=mq331AQKKAFQArABIIACAw%3D%3D#aoh=16396483414600&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.theguardian.com%2Fworld%2F2021%2Fdec%2F15%2Fomicron-found-to-grow-70-times-faster-than-delta-in-bronchial-tissue
So, what we need is a treatment that goes directly to the broncus and upper airway!
Scary thought tho, how quickly this thing can get in and start replicating. The slower tissue infection rate looks promising though.
Is this new or already posted?
The Activ-2 trial had the estimated end date of Q4 2021...
https://www.nih.gov/activ/nih-funded-activ/activ-associated-clinical-trials
"Additional studies are needed to define the role of remdesivir, favipiravir, interferons, ivermectin, dutasteride, proxulutamide, fluvoxamine, bromhexine, nitazoxanide and niclosamid in the treatment of COVID-19."
So they like interferons, but need to learn how it will fit in as a treatment?
Didn't RM say in one of his interviews that he was looking at Synairgen going through the start of the Covid roll out, and then Jv/partner later on.
Basically once they have got value out of the Covid market they would think of using others, but not before?
Less than 3 months from start of trial to approval of Remdesiver?!
Awesome!!
So by April then? ;o)
Could be Reddit, maybe the threat from the variants? I don't think it would take much to start a couple of days of free fall and folk de-risking.
There's a sea of red out there and we're just getting taken down with it.
Deep breath...
Punit,
You rarely have anything useful to say.
You often ask daft questions that really, no-one without a crystal ball can answer.
If not one of the above, your posts are negative and an attempt to stir things up.
Please just shut up and f*** off!
It's a 14 day course, so potentially 2 months after that.
What's it for?
When is the next interim company report due?
Would this give any insight into what you are looking for?
Thanks for the link SYN00GOLD.
So basically the Fast Track is a wee hotline to the FDA to have a chat over coffee to discuss how things are going, and keep both sides up to date over requirements to get it over the line.
Nice.